Triple-negative breast cancer is called “triple-negative” because the tumor lacks all three of these receptors. That absence is exactly what makes it more challenging to treat: These targeted forms of ...

The bispecific ADC izalontamab brengitecan improved survival for patients with metastatic triple-negative breast cancer in a ...

Datroway significantly improves overall and progression-free survival in metastatic triple-negative breast cancer patients ineligible for immunotherapy. TROPION-Breast02 trial results highlight ...

It may be best not to go off-script when it comes to breast cancer. Roughly 1 in 8 US women are expected to be diagnosed with invasive breast cancer at some point. It’s the most common cancer in women ...

In the new study, published March 11 in Science Translational Medicine, the researchers linked DP cells to shorter survival times in patients with advanced breast cancer, especially the aggressive ...

A Chinese phase 3 trial of Bristol Myers Squibb’s antibody-drug conjugate has hit its dual primary survival endpoints, ...

A new nationwide study is shedding light on how the social and environmental realities impact Black women’s lives. Where they live, how they’ve been treated, and the resources around them may ...

KILLEEN, Texas — When Shewanna Strickland went in for a routine mammogram in April 2024, just after turning 50, she never imagined the journey that lay ahead. What started as a concerning spot on her ...

Beta-blockers may fight the progression of triple-negative breast cancer, researchers have found Getty Beta blockers — a commonly prescribed blood pressure medication — may be useful in stopping the ...